Royal Bank of Canada trimmed its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 88.4% in the first quarter, Holdings Channel reports. The firm owned 51,858 shares of the company’s stock after selling 393,734 shares during the period. Royal Bank of Canada’s holdings in ARK Genomic Revolution ETF were worth $1,369,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ascentis Independent Advisors purchased a new position in ARK Genomic Revolution ETF during the first quarter worth about $26,000. PNC Financial Services Group Inc. boosted its position in shares of ARK Genomic Revolution ETF by 53.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock worth $29,000 after purchasing an additional 378 shares during the period. Sunbelt Securities Inc. increased its holdings in ARK Genomic Revolution ETF by 734.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,118 shares of the company’s stock valued at $31,000 after purchasing an additional 984 shares during the last quarter. AlphaCore Capital LLC acquired a new stake in ARK Genomic Revolution ETF in the 4th quarter valued at approximately $39,000. Finally, Hilton Head Capital Partners LLC raised its position in ARK Genomic Revolution ETF by 161.4% in the first quarter. Hilton Head Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $41,000 after purchasing an additional 949 shares during the period.
ARK Genomic Revolution ETF Stock Performance
ARKG opened at $47.73 on Thursday. ARK Genomic Revolution ETF has a 52 week low of $23.42 and a 52 week high of $47.73. The business has a fifty day simple moving average of $40.24 and a 200-day simple moving average of $33.17.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
